The role of general practitioners in the diagnosis and treatment of Alzheimer's disease: A multinational survey

被引:65
作者
Wilkinson, D
Stave, C
Keohane, D
Vincenzino, O
机构
[1] Memory Assessment & Res Ctr, Southampton, Hants, England
[2] Pfizer Inc, New York, NY USA
关键词
Alzheimer's disease; general practitioner; access to care; diagnosis; treatment; survey;
D O I
10.1177/147323000403200207
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Alzheimer's disease (AD) is a growing healthcare problem. Early diagnosis and effective treatment would benefit patients and caregivers, as well as having economic implications. We conducted a survey of 741 caregivers of patients with AD in Australia, France, Italy, Spain and the UK to assess the current situation regarding the diagnosis and treatment of AD in routine clinical practice. The average time from when symptoms were first noticed by the caregiver to making the first doctor's appointment was 4 months, but 22% of caregivers waited more than I year before consulting a doctor. Although the majority of patients (74%) consulted their general practitioner first, the diagnosis was more likely to be made by a specialist; on average, there was a 1-year delay from when symptoms were first noticed by the caregiver to diagnosis. Access to AD care is restricted by many national healthcare systems. The delay in diagnosis imposed by such restrictions impacts on access to early and effective treatment.
引用
收藏
页码:149 / 159
页数:11
相关论文
共 28 条
[1]  
*ALZH EUR, PREV DEM STAT
[2]   The effects of donepezil in Alzheimer's disease -: Results from a multinational trial [J].
Burns, A ;
Rossor, M ;
Hecker, J ;
Gauthier, S ;
Petit, H ;
Möller, HJ ;
Rogers, SL ;
Friedhoff, LT .
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 1999, 10 (03) :237-244
[3]  
Burns Alistair, 2000, Int J Neuropsychopharmacol, V3, P31, DOI 10.1017/S1461145700001905
[4]   Long-term effects of rivastigmine in moderately severe Alzheimer's disease - Does early initiation of therapy offer sustained benefits? [J].
Doraiswamy, PM ;
Krishnan, KRR ;
Anand, R ;
Sohn, H ;
Danyluk, J ;
Hartman, RD ;
Veach, J .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2002, 26 (04) :705-712
[5]   A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease [J].
Farlow, M ;
Anand, R ;
Messina, J ;
Hartman, R ;
Veach, J .
EUROPEAN NEUROLOGY, 2000, 44 (04) :236-241
[6]   A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease [J].
Feldman, H ;
Gauthier, S ;
Hecker, J ;
Vellas, B ;
Subbiah, P ;
Whalen, E .
NEUROLOGY, 2001, 57 (04) :613-620
[7]   Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden [J].
Feldman, H ;
Gauthier, S ;
Hecker, J ;
Vellas, B ;
Emir, B ;
Mastey, V ;
Subbiah, P .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2003, 51 (06) :737-744
[8]   Impact of donepezil on caregiving burden for patients with Alzheimer's disease [J].
Fillit, HM ;
Gutterman, EM ;
Brooks, RL .
INTERNATIONAL PSYCHOGERIATRICS, 2000, 12 (03) :389-401
[9]   The cholinergic hypothesis of Alzheimer's disease: a review of progress [J].
Francis, PT ;
Palmer, AM ;
Snape, M ;
Wilcock, GK .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1999, 66 (02) :137-147
[10]  
Fratiglioni L, 2000, NEUROLOGY, V54, pS10